Literature DB >> 12203111

Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene.

Kristen C Johnson1, Joseph L Kissil, Jessica L Fry, Tyler Jacks.   

Abstract

Mutations in the Nf2 tumor suppressor gene lead to tumor formation in humans and mice and cellular overproliferation phenotypes in Drosophila. The Nf2 encoded protein, merlin, shares close sequence similarity in its amino terminus to members of the band 4.1 family of membrane-cytoskeletal linkers. Similarities between merlin and this family suggest a role for merlin in regulating cytoskeletal function. However, the mechanism of the tumor suppressing activity of merlin is not yet understood. Mutational analysis of Nf2 in flies has led to the identification of a dominant-negative allele, which harbors mutations in the amino terminus of the protein. Here, we report that expression of a murine analog of this amino-terminal mutant of Nf2 leads to complete transformation of NIH3T3 fibroblasts in culture. Cells that express this Nf2 mutant allele display disruptions of the actin cytoskeleton, lack of contact inhibition of growth, and anchorage-independent growth. Finally, fibroblasts that express this mutant Nf2 allele form tumors when injected into nude mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203111     DOI: 10.1038/sj.onc.1205693

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

Review 1.  Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.

Authors:  Wei Li; Jonathan Cooper; Matthias A Karajannis; Filippo G Giancotti
Journal:  EMBO Rep       Date:  2012-03       Impact factor: 8.807

2.  The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex.

Authors:  Andrew B Gladden; Alan M Hebert; Eveline E Schneeberger; Andrea I McClatchey
Journal:  Dev Cell       Date:  2010-11-16       Impact factor: 12.270

3.  Schwannomin/merlin promotes Schwann cell elongation and influences myelin segment length.

Authors:  Courtney Thaxton; Marga Bott; Barbara Walker; Nicklaus A Sparrow; Stephen Lambert; Cristina Fernandez-Valle
Journal:  Mol Cell Neurosci       Date:  2010-12-21       Impact factor: 4.314

4.  Cell-cell contact globally activates microRNA biogenesis.

Authors:  Hun-Way Hwang; Erik A Wentzel; Joshua T Mendell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

Review 5.  At the crossroads of polarity, proliferation and apoptosis: the use of Drosophila to unravel the multifaceted role of endocytosis in tumor suppression.

Authors:  Thomas Vaccari; David Bilder
Journal:  Mol Oncol       Date:  2009-06-06       Impact factor: 6.603

Review 6.  Targeting Pyk2 for therapeutic intervention.

Authors:  Christopher A Lipinski; Joseph C Loftus
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

7.  The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Authors:  Katherine Striedinger; Scott R VandenBerg; Gilson S Baia; Michael W McDermott; David H Gutmann; Anita Lal
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

8.  Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2.

Authors:  Chunling Yi; Erik W Wilker; Michael B Yaffe; Anat Stemmer-Rachamimov; Joseph L Kissil
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation.

Authors:  E E Bosco; Y Nakai; R F Hennigan; N Ratner; Y Zheng
Journal:  Oncogene       Date:  2010-02-15       Impact factor: 9.867

10.  p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.

Authors:  Hoi Yee Chow; Dina Stepanova; Jennifer Koch; Jonathan Chernoff
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.